<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176161</url>
  </required_header>
  <id_info>
    <org_study_id>WUH 14015</org_study_id>
    <secondary_id>18-01662</secondary_id>
    <nct_id>NCT02176161</nct_id>
  </id_info>
  <brief_title>Metformin Prostate Cancer Adjuvant Trial</brief_title>
  <official_title>Phase II Clinical Study of Effect of Metformin on Prostate Specific Antigen Doubling Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II clinical study to determine if Metformin can increase Prostate Specific&#xD;
      Antigen (PSA) doubling time for patients with Prostate Cancer who have failed primary&#xD;
      treatment with radiation, or surgical patients that are at high risk for recurrence based on&#xD;
      surgical pathology. Men with confirmed prostate cancer and rising serum PSA levels will&#xD;
      receive Metformin and will be monitored for PSA response and disease progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer patients who have received treatment with radiation therapy or surgery, who&#xD;
      have indicators of high-risk disease will be administered 750mg Metformin Extended Release&#xD;
      twice per day for a period of 9 months. Metformin is an FDA-approved drug that is prescribed&#xD;
      to treat high blood sugar levels in patients with Type 2 Diabetes. To track prostate cancer&#xD;
      response in study participants, investigators will obtain prostate specific antigen (PSA)&#xD;
      levels every three months for the duration of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate Specific Antigen Doubling Time</measure>
    <time_frame>9 months</time_frame>
    <description>Determine if Metformin treatment can increase Prostate Specific Antigen Doubling time over 9 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease Prostate Specific Antigen Levels</measure>
    <time_frame>9 months</time_frame>
    <description>Determine if treatment with Metformin will decrease serum Prostate Specific Antigen levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Surgical Prostate Cancer Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radical Prostatectomy patients with:&#xD;
High risk surgical pathology (Gleason 8 or higher, positive surgical margins, evidence of extra capsular extension or seminal vesicle invasion)&#xD;
Prior Radiation Therapy OR&#xD;
Prior Radiation Therapy with rising PSA.&#xD;
Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation Patients with Biochemical Recurrence (rising PSA).&#xD;
Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride Extended Release 750mg</intervention_name>
    <description>Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.</description>
    <arm_group_label>Radiation Patients</arm_group_label>
    <arm_group_label>Surgical Prostate Cancer Patients</arm_group_label>
    <other_name>Glucophage XR</other_name>
    <other_name>Glumetza XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male &gt; 18 years of age&#xD;
&#xD;
          -  Biopsy confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  Hemoglobin A1C &lt;7.0%&#xD;
&#xD;
          -  Able and willing to participate in the full 12 months of the study&#xD;
&#xD;
          -  Able to understand instructions related to study procedures&#xD;
&#xD;
          -  Able to read and write English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic Prostate Cancer&#xD;
&#xD;
          -  Prostate Specific Antigen Doubling Time &lt; 6 months&#xD;
&#xD;
          -  Prior Chemotherapy, hormonal therapy, oral glucocorticoid therapy,&#xD;
             Gonadotropin-releasing hormone analogue therapy&#xD;
&#xD;
          -  Current or previous use of 5Î±-reductase inhibitors, antiandrogen drugs, metformin,&#xD;
             oral or injectable diabetes drug&#xD;
&#xD;
          -  Diagnosis of Type 1 Diabetes Mellitus&#xD;
&#xD;
          -  Known hypersensitivity to metformin&#xD;
&#xD;
          -  any condition associated with increased risk of metformin associated lactic acidosis&#xD;
&#xD;
          -  participation in any investigational or marketed drug trial within 30 days prior to&#xD;
             screening or during study period&#xD;
&#xD;
          -  any unstable, serious co-existing medical conditions including but not limited to&#xD;
             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,&#xD;
             clinically evident congestive heart failure, or cerebrovascular accident within 6&#xD;
             months prior to screening&#xD;
&#xD;
          -  history of megaloblastic anemia&#xD;
&#xD;
          -  abnormal liver function test (total bilirubin, aspartate aminotransferase, alanine&#xD;
             aminotransferase, alkaline phosphatase or serum creatinine above upper limit of&#xD;
             normal)&#xD;
&#xD;
          -  history of other malignancies, with the exception of adequately treated non-melanoma&#xD;
             skin cancer, stage 1 melanoma, non-muscle invasive bladder cancer, or other solid&#xD;
             tumors curatively treated with no evidence of disease for at least 5 years&#xD;
&#xD;
          -  history or current evidence of substance abuse within 12 months of screening&#xD;
&#xD;
          -  history of any illness (including psychiatric) that, in the opinion of the&#xD;
             investigator, might confound the results of the study or post an additional risk to&#xD;
             the subject&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron E Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Winthrop Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Palmer, PhD</last_name>
    <phone>516-535-4187</phone>
    <email>mary.palmer@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aaron E Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Prostate Cancer Recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

